This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

HPV Vaccination Does Not Lead To An Increase In Sex

Stocks in this article: ENL RUK

AMSTERDAM, October 10, 2012 /PRNewswire/ --

A study published in Vaccine reveals that contrary to recent discussions, the HPV vaccination does not increase sexual activity in adolescent girls

There have been claims recently that the HPV (Human papillomavirus) vaccination increases sexual activity in adolescent girls as it effectively gives them a 'green light' to have sex because of a perceived protection against sexually transmitted infections. This study published in Vaccine, examines whether or not there is any influence on sexual behaviour as a result of being offered or given the vaccination.

The study looked at a cross-section of over 1,052 girls in the UK, with a mean age of 17.1 years. Of these, 433 had been offered the HPV vaccine and 620 had not yet been offered the vaccine. Results showed that the group of girls who had been offered the HPV vaccine were no more likely to be sexually active than the group of girls who had not yet been offered it. Those who had been vaccinated (148 participants), were no more likely to have changed their condom use or increased their total number of sexual partners than the unvaccinated group (259 participants); providing evidence that neither being offered the vaccine or receiving the vaccine has an effect on the sexual behaviour of adolescent girls.

Notes for editors

This article is "Human papillomavirus vaccination and sexual behaviour: Cross-sectional and longitudinal surveys conducted in England" by Alice S. Forster, Laura A.V. Marlow, Judith Stephenson, Jane Wardle and Jo Waller (DOI 10.1016/j.vaccine.2012.05.053) and appears in Vaccine published by Elsevier.

The article is available to credentialed journalists at no charge through free access to ScienceDirect, the world's largest repository of scientific information. Please use your ScienceDirect media login and password to access the full text research paper. For a new media login, forgotten password or if you have any specific questions, please contact newsroom@elsevier.com 

If you are a credentialed journalist and are interested in receiving other research alerts from Elsevier, please sign up for Elsevier's Monthly Research Selection (EMRS) - a monthly email developed by the Elsevier Newsroom which highlights new, interesting, interesting or otherwise intriguing research articles for health and science media. The full text research articles included are peer reviewed and have been publicly available for no more than 4-6 weeks (they are usually articles-in-press). They have not been press-released nor covered in the media (that we are aware of) and they are not embargoed.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs